Cost Of Revenue - Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 149.4 USD -1.2%

Updated:

Alnylam Pharmaceuticals Inc
Cost of Revenue

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Alnylam Pharmaceuticals Inc
Cost of Revenue Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Cost of Revenue	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Alnylam Pharmaceuticals Inc NASDAQ:ALNY	Cost of Revenue -$321.5m	CAGR 3-Years -50%	CAGR 5-Years -129%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Cost of Revenue -$18.2B	CAGR 3-Years -6%	CAGR 5-Years -19%	CAGR 10-Years -15%
	Gilead Sciences Inc NASDAQ:GILD	Cost of Revenue -$6.6B	CAGR 3-Years -10%	CAGR 5-Years -7%	CAGR 10-Years -8%
	Amgen Inc NASDAQ:AMGN	Cost of Revenue -$9.9B	CAGR 3-Years -17%	CAGR 5-Years -19%	CAGR 10-Years -10%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Cost of Revenue -$1.3B	CAGR 3-Years -20%	CAGR 5-Years -25%	CAGR 10-Years -26%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Cost of Revenue -$1.8B	CAGR 3-Years -14%	CAGR 5-Years -30%	CAGR 10-Years -27%

See Also

Based on the financial report for Mar 31, 2024, Alnylam Pharmaceuticals Inc's Cost of Revenue amounts to -321.5m USD.

Over the last year, the Cost of Revenue growth was -71%. The average annual Cost of Revenue growth rates for Alnylam Pharmaceuticals Inc have been -50% over the past three years , -129% over the past five years .

Join more than 138,200+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.